9.200USD+5.26%Mkt Cap: 656.73M USDP/E: —Last update: 2026-06-01
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Aus…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap656.73M USD
Enterprise Value400.16M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-29.44M USD
Revenue/Share—
Last Price9.200 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees21
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-13.90
PEG—
EV/EBITDA-11.19
EV/Revenue—
P/S—
P/B5.66
EPS (TTM)-0.92
EPS (Forward)-0.65
52W Range
1.87075% of range11.61
52W High11.61 USD
52W Low1.870 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-31.39%
ROA-28.08%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-23.93M USD
CapEx (TTM)732.92K USD
FCF Margin—
FCF Yield-3.05%
Net Debt-89.54M USD
Net Debt/EBITDA2.50
Balance Sheet
Debt/Equity0.01
Current Ratio8.76
Quick Ratio8.59
Book Value/Sh1.591 USD
Cash/Share1.665 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Target (Mean)18.46 USD
Target Range14.50 USD – 22.78 USD
# Analysts5
Ownership
Shares Out.71.19M
Float40.34M
Insiders17.50%
Institutions38.92%
Short Interest
Short Ratio4.4d
Short % Float7.65%
Short % Out.5.92%
Shares Short3.22M
Short (prev mo.)2.96M
Technical
SMA 509.347 (-1.6%)
SMA 2005.827 (+57.9%)
Beta—
S&P 52W Chg27.94%
Avg Vol (30d)1.03M
Avg Vol (10d)1.88M
Technical Indicators
RSI (14)42.7
MACD-0.1993
MACD Signal-0.0898
MACD Hist.-0.1094
BB Upper10.71 USD
BB Middle9.430 USD
BB Lower8.150 USD
BB Width27.14%
ATR (14)0.7393 USD
Vol Ratio (20d)0.38x